Corbus Pharmaceuticals files $127.5 million at-the-market stock offering

Corbus Pharmaceuticals Holdings filed a prospectus supplement dated August 7, 2026, for an at-the-market equity program conducted through Jefferies LLC. Under the arrangement, Corbus may offer and sell shares of its common stock for a combined price up to $127,500,000 over time, with Jefferies LLC acting as sales agent.¹ The stock trades on Nasdaq under the ticker CRBP, and its last reported sale price on August 4, 2026 was $9.40 per share.¹

Jefferies is not obligated to sell a set amount of stock. The firm will use commercially reasonable efforts consistent with its normal trading and sales practices, on terms mutually agreed with Corbus.¹ Jefferies will earn a fixed commission of 3% of the gross sales price per share sold.¹

Corbus said it intends to use net proceeds to fund continued development of CRB-701, CRB-913 and other pre-clinical compounds, along with general corporate purposes that could include acquisitions, working capital, debt reduction and capital expenditures.¹

The filing also detailed potential dilution. Corbus's net tangible book value as of June 30, 2026 was about $98.5 million, or $5.27 per share, and after accounting for 738,707 shares sold under the sale agreement following that date, pro forma net tangible book value would have been about $105.1 million, or $5.42 per share.¹ Assuming the full $127.5 million raise at $9.40 per share, pro forma as-adjusted net tangible book value would rise to about $228.7 million, or $6.94 per share, an increase of $1.52 per share for existing holders but a $2.46 per share dilution for new investors in the offering.¹

The company noted its stock price fluctuated between a high of $20.56 and a low of $7.12 per share from August 1, 2025 through August 1, 2026.¹